Letter to Congress Regarding Legislation That Would Change the FDA’s Accelerated-Approval Program for New Drugs

View as PDF

In a letter to the Committee on Energy & Commerce’s Subcommittee on Health in the U.S. House of Representatives, Public Citizen urged the subcommittee to oppose H.R. 6996, the Accelerating Access for Patients Act of 2022, and instead support H.R. 6963, the Accelerated Approval Integrity Act of 2022.